CUE BIOPHARMA INC (CUE:NASDAQ)
$0.6152 -0.1091 (-15.0628%)
Analysed CUE BIOPHARMA INC (CUE:NASDAQ) News Sources
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
15-04-2026
yahoo.com
The VIX Sharply Reverses and Points Back Towards 30 After Failed Peace Negotiations
13-04-2026
247wallst.com
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
08-04-2026
yahoo.com
Cue Biopharma Announces CEO Transition
27-03-2026
yahoo.com
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
26-03-2026
yahoo.com
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
16-03-2026
yahoo.com
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
09-03-2026
yahoo.com
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
17-02-2026
yahoo.com
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
12-02-2026
yahoo.com
Cue Biopharma Announces Pricing of $10 Million Public Offering
19-12-2025
yahoo.com
What is the current price of CUE BIOPHARMA INC (CUE:NASDAQ)?
The current price of CUE BIOPHARMA INC (CUE:NASDAQ) is $0.6152.
CUE BIOPHARMA INC (CUE:NASDAQ) absolute price change since previous trading day?
The absolute price change of CUE BIOPHARMA INC (CUE:NASDAQ) since the previous trading day is $-0.1091.
CUE BIOPHARMA INC (CUE:NASDAQ) percentage price change since previous trading day?
The percentage price change of CUE BIOPHARMA INC (CUE:NASDAQ) since the previous trading day is -15.0628%.
What is the most recent average sentiment score for CUE BIOPHARMA INC (CUE:NASDAQ)?
The most recent average sentiment score for CUE BIOPHARMA INC (CUE:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for CUE BIOPHARMA INC (CUE:NASDAQ)?
The most recent sentiment for CUE BIOPHARMA INC (CUE:NASDAQ) is .
SEC-8K** Filing Available For CUE BIOPHARMA INC (CUE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.